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Conclusions: Following CRT for gastric cancer, spleen volume 
decreased progressively and radiation-dose dependently to 
below normal, and to a third of its original size at 4 years. 
Thromboembolic and infectious events were observed in 28% 
of our patients. Although these events were not related to 
radiation dose, this study emphasises the need for 
prospective research on the consequences after irradiation of 
the spleen. 
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Purpose/Objective: The prognosis of pathological T2-3N0M0 
(pT2-3N0M0) thoracic esophageal squamous cell carcinoma 
(TESCC) after radical surgery is poor and neither adjuvant 
chemotherapy nor two-dimensional radiotherapy provided 
survival benefit. However, the distinct dosimetric advantages 
of three-dimensional radiotherapy (3DRT) techniques, such as 
intensity-modulated radiotherapy or three-dimensional 
conformal radiotherapy, provide theoretical possibility of 
survival benefit. This study was designed to assess the 
clinical value of adjuvant 3DRT after radical surgery 
compared with surgery alone for pT2-3N0M0 TESCC. 
Materials and Methods: We compared the overall survival 
(OS) , disease free survival (DFS) and recurrences of the 96 
consecutive patients receiving adjuvant 3DRT after surgery 
(S+3DRT) from 2004 to 2011 with that of 820 consecutive 
patients undergoing surgery alone (S alone) 
contemporaneously in our hospital as a control. The 
prescribed dose was 50-60 Gy to 95% of the planning target 
volume, encompassing the tumor bed and lymphatic drainage 
regions with high risk. Cox regression model was used to 
perform univariate and multivariate analyses of the effect of 
covariates on OS and DFS. Sensitivity analyses and propensity 
score-matched analyses were used for further confirmation. 
Results: Group S+3DRT had more patients with tumor length 
≥5cm and T3 stage than group S alone (P<0.05, both), while 
other characteristics were comparable. The median follow-up 
was 46.4 (3.1-127.2) months for the entire cohort and 60.3 
(28.9-127.2) months for the surviving patients. The rate of 5-
year OS and DFS for group S+3DRT versus group S alone was 
74.3% versus 59.9% (P=0.010), and 71.0% versus 51.7% 
(P=0.003), respectively (Figure A1, A2). Multivariate Cox 
regression analyses revealed group S+3DRT was 
independently associated with an improved OS (Hazard ratio 
[HR] = 0.629, P=0.030) and DFS (HR=0.565, P=0.004) 
compared with group S alone (Table). Sensitivity analyses 
demonstrated that S+3DRT maintained its significance both in 
patients with number of nodes harvested ≥25 (P=0.025 for 
OS; P=0.046 for DFS) and in patients with DFS ≥9 months 
(P=0.041 for OS; and P=0.006 for DFS). Propensity score-
matched analyses also comfirmed the improved 5-year OS 
(P=0.035) and DFS (P=0.025) in group S+3DRT versus group S 
alone (Figure B1, B2). The incidence rate of overall 
recurrence, locoregional recurrence and distant metastasis 
for group S+3DRT versus group S alone was 22.9% versus 
43.0% (P<0.001), 18.8% versus 35.2% (P=0.001), and 11.5% 
versus 21.3% (P=0.024), respectively. No grade 4 to 5 
radiation-related toxicities were observed in group S+3DRT, 
both early and late grade 3 toxicities developed in 25 
patients (26.0%).  
 
 
Conclusions: Compared with surgery alone, adjuvant 3DRT 
reduces locoregional recurrences and distant metastases, 
resulting in improved DFS and OS with tolerable toxicities for 
pT2-3N0M0 TESCC. 
   
 
 
 
